Investors

Mikrobiomik is a biopharmaceutical company founded for the research, development, production and commercialization of biologic medicines based on the human microbiome.

At Mikrobiomik we are developing a new generation of biologic medicines based on the human microbiome, focused on serious diseases, currently without therapeutic alternative such as non-alcoholic steatohepatitis, acute diverticulitis or some types of metastatic cancers.

Our investigational biological medicine, MBK-01, given to patients in the completed ICD-01 clinical trial, has demonstrated clinical results proving non-inferiority to the standard treatment (fidaxomicin) and superiority in the treatment of recurrences, as well as confirming the safety of the medicine.
Mikrobiomik is progressing in a Phase IIa clinical trial for the treatment of acute uncomplicated diverticulitis, a trial authorized in November 2024 by the AEMPS, which is expected to start recruiting patients by 2025. This study is being carried out in partnership with IRICYS, as part of the framework collaboration agreement.

Shareholders

Our current shareholders, in addition to the founding partners, include:

  • Orza, a direct investment entity, belonging to the Elkarkidetza and Geroa pension funds.
  • Seed Capital Bizkaia, a public company attached to the Department of Economic Promotion of the Provincial Council of Bizkaia, which is strongly committed to fostering innovation, social impact and the promotion and regeneration of the entrepreneurial network in Bizkaia.
  • San Ignacio S.L, a “family office” specially oriented to support disruptive projects.

News

MARCH 2025

Capital increase €1.6 M

We have confirmed a capital increase worth €1.6 million. This new milestone has been achieved thanks to the contribution of most of Mikrobiomik’s current partners.

Three new investors have joined this new round of financing, two of which are family offices from Spain and one is a business angel directly related to the global pharmaceutical industry.

APRIL 2024

We are launching a strategic investment round together with CaixaBank to launch MBK-01

Mikrobiomik has given CaixaBank CIB the exclusive mandate to assist in the search for potential investors for this round of capital, aimed primarily at Venture Capital, both national and international; Corporate Capital; institutional investors and professional Family Offices.

The funds raised will be used mainly to expand Mikrobiomik’s manufacturing capacity to meet the expected demand for the biological medicine MBK-01. It will also help to increase our current staff of 20 people, to accelerate other clinical trials the company has underway and to launch new projects currently in its pipeline.

MARCH 2024

Capital increase €1 M

A new capital increase for the amount of 1 million euros, has been completed. This new fund raising is another accomplishment that demonstrates the commitment of the current partners with the company and Mikrobiomik project.

One of the main uses of the funds will be to cover the costs associated with the regulatory strategy to bring MBK-01 to market.

SEPTEMBER 2023

Capital increase €1.1 M

We have confirmed a capital increase worth 1.1 million euros. This milestone is materialized thanks to the exclusive contribution of its current partners, who are determined to fulfill their initial mission: launch their investigational biological medicine, MBK-01, onto the European market.

Since its founding in 2018, Mikrobiomik has raised a significant sum of capital, demonstrating the trust and support of partners, such as Orza and Seed Capital Bizkaia. In addition, 11 other partners, including family offices and founding partners, have believed in the project since its inception.